FDA Issues Guidance for Combination Hypertension Drugs

International Pharmaceutical Regulatory Monitor
A A
The FDA released final guidance for sponsors of fixed-combination hypertension drugs, with several clarifications of the draft document.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00